FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2299861306> ?p ?o ?g. }

• W2299861306 endingPage "683" @default.
• W2299861306 startingPage "683" @default.
• W2299861306 abstract "<h3>Importance</h3> Immunosuppression (IS), such as in solid-organ transplant recipients (SOTRs) and patients with human immunodeficiency virus (HIV) or hematologic malignant neoplasms, increases the risk of developing nonmelanoma skin cancers (NMSCs). However, it is unknown whether IS patients are at increased risk of developing NMSCs with aggressive subclinical extensions (NMSC-ASE), which may extend aggressively far beyond conventional surgical margins. <h3>Objective</h3> To study clinical characteristics of NMSC-ASE among immunocompetent (IC) and various subgroups of IS patients and to suggest a predictive model for NMSC-ASE lesions. <h3>Design, Setting, and Participants</h3> A 6-year retrospective review of 2998 NMSC cases between February 26, 2007, and February 17, 2012, at the Dermatologic and Mohs Micrographic Surgery Unit of the University of California, San Diego, Medical Center. Nonmelanoma skin cancers that required at least 3 Mohs micrographic surgery stages with final surgical margins of at least 10 mm were defined as ASE lesions. All cases were categorized into 1 of 2 groups, IS or IC. Immunosuppressed cases were further subcategorized into 3 subgroups: SOTRs and patients with HIV or hematologic malignant neoplasm. The data were analyzed in December 2012. <h3>Main Outcomes and Measures</h3> We evaluated the odds ratio of having NMSC-ASE lesions in IS patients (SOTRs, HIV, hematologic malignant neoplasm) compared with IC patients. Other clinical characteristics and preoperative risks were analyzed and compared. <h3>Results</h3> Of all 2998 cases, we identified 805 NMSC-ASE cases: 137 IS and 668 IC. Immunosuppressed patients had an odds ratio of 1.94 of having ASE lesions compared with IC patients (95% CI, 1.54-2.44;<i>P</i> < .001). Additionally, the SOTR subgroup was associated with a 2.74 odds of having NSMC-ASE compared with non-SOTRs (95% CI, 2.00-3.76;<i>P</i> < .001), and the presence of hematologic malignant neoplasm was associated with 1.74 times the odds compared with IC patients (95% CI, 1.04-2.90;<i>P</i> = .04)<i>.</i>Multivariate analysis found older age (<i>P</i> < .001), lesion locations such as zone 1 (OR, 1.39 [95% CI, 1.04-1.85];<i>P</i> = .02) or zone 2 (OR, 1.45 [95% CI, 1.08-1.94];<i>P</i> = .01), and IS status (OR, 1.94 [95% CI, 1.54-2.44];<i>P</i> < <i>.</i>001) to be significant predictors of ASE. <h3>Conclusions and Relevance</h3> The findings of this study suggest an increased risk for NMSC-ASE lesions in IS patients, especially in SOTRs and those with hematologic malignant neoplasm, but not patients with HIV. Statistically significant predictors of NMSC-ASE lesions such as age, location, and IS status can help physicians choose the most appropriate treatment modalities and optimize surgical planning." @default.
• W2299861306 created "2016-06-24" @default.
• W2299861306 creator A5000800064 @default.
• W2299861306 creator A5015009065 @default.
• W2299861306 creator A5031231007 @default.
• W2299861306 creator A5040232814 @default.
• W2299861306 creator A5063858141 @default.
• W2299861306 creator A5070429055 @default.
• W2299861306 date "2016-06-01" @default.
• W2299861306 modified "2023-10-16" @default.
• W2299861306 title "Nonmelanoma Skin Cancer With Aggressive Subclinical Extension in Immunosuppressed Patients" @default.
• W2299861306 cites W1534751674 @default.
• W2299861306 cites W1582375825 @default.
• W2299861306 cites W18451002 @default.
• W2299861306 cites W1966584824 @default.
• W2299861306 cites W1969744845 @default.
• W2299861306 cites W1979588282 @default.
• W2299861306 cites W1981432623 @default.
• W2299861306 cites W1986472980 @default.
• W2299861306 cites W1996192244 @default.
• W2299861306 cites W2008976442 @default.
• W2299861306 cites W2025025945 @default.
• W2299861306 cites W2034188915 @default.
• W2299861306 cites W2040600853 @default.
• W2299861306 cites W2049460731 @default.
• W2299861306 cites W2058822373 @default.
• W2299861306 cites W2060328350 @default.
• W2299861306 cites W2073460342 @default.
• W2299861306 cites W2093849307 @default.
• W2299861306 cites W2100623045 @default.
• W2299861306 cites W2104433241 @default.
• W2299861306 cites W2119003182 @default.
• W2299861306 cites W2119665774 @default.
• W2299861306 cites W2124754149 @default.
• W2299861306 cites W2137688229 @default.
• W2299861306 cites W2142296228 @default.
• W2299861306 cites W2147133104 @default.
• W2299861306 cites W2147763384 @default.
• W2299861306 cites W2154872776 @default.
• W2299861306 cites W2170102686 @default.
• W2299861306 cites W2331672140 @default.
• W2299861306 cites W2431753579 @default.
• W2299861306 cites W2798576213 @default.
• W2299861306 doi "https://doi.org/10.1001/jamadermatol.2016.0192" @default.
• W2299861306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26981734" @default.
• W2299861306 hasPublicationYear "2016" @default.
• W2299861306 type Work @default.
• W2299861306 sameAs 2299861306 @default.
• W2299861306 citedByCount "24" @default.
• W2299861306 countsByYear W22998613062016 @default.
• W2299861306 countsByYear W22998613062017 @default.
• W2299861306 countsByYear W22998613062018 @default.
• W2299861306 countsByYear W22998613062019 @default.
• W2299861306 countsByYear W22998613062020 @default.
• W2299861306 countsByYear W22998613062021 @default.
• W2299861306 countsByYear W22998613062022 @default.
• W2299861306 countsByYear W22998613062023 @default.
• W2299861306 crossrefType "journal-article" @default.
• W2299861306 hasAuthorship W2299861306A5000800064 @default.
• W2299861306 hasAuthorship W2299861306A5015009065 @default.
• W2299861306 hasAuthorship W2299861306A5031231007 @default.
• W2299861306 hasAuthorship W2299861306A5040232814 @default.
• W2299861306 hasAuthorship W2299861306A5063858141 @default.
• W2299861306 hasAuthorship W2299861306A5070429055 @default.
• W2299861306 hasBestOaLocation W22998613061 @default.
• W2299861306 hasConcept C113280763 @default.
• W2299861306 hasConcept C121608353 @default.
• W2299861306 hasConcept C126322002 @default.
• W2299861306 hasConcept C156957248 @default.
• W2299861306 hasConcept C16005928 @default.
• W2299861306 hasConcept C2777789703 @default.
• W2299861306 hasConcept C2778334829 @default.
• W2299861306 hasConcept C2780252810 @default.
• W2299861306 hasConcept C71924100 @default.
• W2299861306 hasConceptScore W2299861306C113280763 @default.
• W2299861306 hasConceptScore W2299861306C121608353 @default.
• W2299861306 hasConceptScore W2299861306C126322002 @default.
• W2299861306 hasConceptScore W2299861306C156957248 @default.
• W2299861306 hasConceptScore W2299861306C16005928 @default.
• W2299861306 hasConceptScore W2299861306C2777789703 @default.
• W2299861306 hasConceptScore W2299861306C2778334829 @default.
• W2299861306 hasConceptScore W2299861306C2780252810 @default.
• W2299861306 hasConceptScore W2299861306C71924100 @default.
• W2299861306 hasIssue "6" @default.
• W2299861306 hasLocation W22998613061 @default.
• W2299861306 hasLocation W22998613062 @default.
• W2299861306 hasOpenAccess W2299861306 @default.
• W2299861306 hasPrimaryLocation W22998613061 @default.
• W2299861306 hasRelatedWork W1999472182 @default.
• W2299861306 hasRelatedWork W2000804075 @default.
• W2299861306 hasRelatedWork W2110386876 @default.
• W2299861306 hasRelatedWork W2115725509 @default.
• W2299861306 hasRelatedWork W2147133104 @default.
• W2299861306 hasRelatedWork W2153216907 @default.
• W2299861306 hasRelatedWork W3102741523 @default.
• W2299861306 hasRelatedWork W3110117735 @default.
• W2299861306 hasRelatedWork W4232091092 @default.
• W2299861306 hasRelatedWork W999154016 @default.

• next